TBK1 - New-wiki

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	AGAP2	ArfGAP with GTPase domain, ankyrin repeat and PH domain 2	Netrin-1 signaling
Novel	AVIL	advillin
Novel	MARCHF9	membrane associated ring-CH-type finger 9
Novel	MPP3	MAGUK p55 scaffold protein 3
Novel	SCN7A	sodium voltage-gated channel alpha subunit 7	Interaction between L1 and Ankyrins Phase 0 - rapid depolarisation	Ranolazine Topiramate Valproic acid Lamotrigine Carbamazepine Oxcarbazepine Cocaine Promethazine Brivaracetam Tetracaine Amylocaine Propoxycaine Pramocaine Pentoxyverine Dichlorobenzyl alcohol Bioallethrin Fish oil
Novel	SOCS2	suppressor of cytokine signaling 2	Interleukin-7 signaling Neddylation Negative regulation of FLT3 Growth hormone receptor signaling
Novel	YAF2	YY1 associated factor 2	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known Transcriptional Regulation by E2F6
	AGO2	argonaute RISC catalytic component 2	Pre-NOTCH Transcription and Translation MicroRNA (miRNA) biogenesis Ca2+ pathway Small interfering RNA (siRNA) biogenesis Post-transcriptional silencing by small RNAs Transcriptional regulation by small RNAs TP53 Regulates Metabolic Genes MAPK6/MAPK4 signaling Regulation of RUNX1 Expression and Activity Regulation of PTEN mRNA translation Competing endogenous RNAs (ceRNAs) regulate PTEN translation Transcriptional Regulation by MECP2 Transcriptional Regulation by MECP2 Estrogen-dependent gene expression Regulation of MECP2 expression and activity NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
	APP	amyloid beta precursor protein	Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1 activates NFkB by phosphorylation and activation of IKKs complex The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Tromethamine Phenserine Tetrathiomolybdate CAD106 Mito-4509 Edonerpic Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F) Zinc acetate Aluminium phosphate Aluminum acetate Zinc chloride Zinc sulfate, unspecified form	Alzheimer's disease (AD)
	ATG9A	autophagy related 9A	Macroautophagy
	AZI2	5-azacytidine induced 2
	CALCOCO2	calcium binding and coiled-coil domain 2
	CDC37	cell division cycle 37, HSP90 cochaperone	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Constitutive Signaling by EGFRvIII Regulation of necroptotic cell death Downregulation of ERBB2 signaling RHOBTB2 GTPase cycle Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants
	CDC42BPG	CDC42 binding protein kinase gamma		Fostamatinib
	CYLD	CYLD lysine 63 deubiquitinase	NOD1/2 Signaling Pathway TNFR1-induced proapoptotic signaling Regulation of TNFR1 signaling TNFR1-induced NFkappaB signaling pathway Ub-specific processing proteases Negative regulators of DDX58/IFIH1 signaling		Familial cylindromatosis Multiple familial trichoepithelioma Brooke-Spiegler syndrome
	HSP90AA1	heat shock protein 90 alpha family class A member 1	Signaling by ERBB2 Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation vRNP Assembly Regulation of actin dynamics for phagocytic cup formation eNOS activation Regulation of PLK1 Activity at G2/M Transition Scavenging by Class F Receptors Scavenging by Class F Receptors HSP90 chaperone cycle for steroid hormone receptors (SHR) HSF1 activation Attenuation phase HSF1-dependent transactivation Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Sema3A PAK dependent Axon repulsion VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway VEGFR2 mediated vascular permeability Uptake and function of diphtheria toxin PIWI-interacting RNA (piRNA) biogenesis Anchoring of the basal body to the plasma membrane Constitutive Signaling by EGFRvIII Regulation of necroptotic cell death Interleukin-4 and Interleukin-13 signaling Neutrophil degranulation The role of GTSE1 in G2/M progression after G2 checkpoint AURKA Activation by TPX2 Downregulation of ERBB2 signaling ESR-mediated signaling Extra-nuclear estrogen signaling RHOBTB2 GTPase cycle Estrogen-dependent gene expression Chaperone Mediated Autophagy Constitutive Signaling by Overexpressed ERBB2 Aggrephagy Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants Potential therapeutics for SARS	Rifabutin Nedocromil 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine Geldanamycin 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine Quercetin 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE Tanespimycin SNX-5422 N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol CCT-018159 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE Copper Polaprezinc Alvespimycin
	HSP90AB1	heat shock protein 90 alpha family class B member 1	Regulation of actin dynamics for phagocytic cup formation HSP90 chaperone cycle for steroid hormone receptors (SHR) HSF1 activation Attenuation phase HSF1-dependent transactivation Sema3A PAK dependent Axon repulsion Uptake and function of diphtheria toxin Neutrophil degranulation The NLRP3 inflammasome The role of GTSE1 in G2/M progression after G2 checkpoint Aryl hydrocarbon receptor signalling ESR-mediated signaling RHOBTB2 GTPase cycle Estrogen-dependent gene expression Chaperone Mediated Autophagy Purinergic signaling in leishmaniasis infection Potential therapeutics for SARS	Geldanamycin 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine Radicicol Tanespimycin SNX-5422 CCT-018159 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE 4-{4-[4-(3-AMINOPROPOXY)PHENYL]-1H-PYRAZOL-5-YL}-6-CHLOROBENZENE-1,3-DIOL (5E)-14-CHLORO-15,17-DIHYDROXY-4,7,8,9,10,11-HEXAHYDRO-2-BENZOXACYCLOPENTADECINE-1,12(3H,13H)-DIONE (5Z)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE (5E)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE (5Z)-13-CHLORO-14,16-DIHYDROXY-3,4,7,8,9,10-HEXAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,11(12H)-DIONE METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE 2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE Polaprezinc
	IKBKB	inhibitor of nuclear factor kappa B kinase subunit beta	Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling p75NTR recruits signalling complexes NF-kB is activated and signals survival FCERI mediated NF-kB activation TAK1 activates NFkB by phosphorylation and activation of IKKs complex Regulation of TNFR1 signaling TNFR1-induced NFkappaB signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation	Mesalazine Sulfasalazine Acetylsalicylic acid Auranofin Arsenic trioxide MLN0415 Acetylcysteine Ertiprotafib Fostamatinib
	IKBKG	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling FCERI mediated NF-kB activation TAK1 activates NFkB by phosphorylation and activation of IKKs complex activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 SUMOylation of immune response proteins Regulation of TNFR1 signaling TNFR1-induced NFkappaB signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Ub-specific processing proteases Ovarian tumor domain proteases Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation	AGRO100 Tarenflurbil	Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect Incontinentia pigmenti Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
	IRF3	interferon regulatory factor 3	ISG15 antiviral mechanism IRF3 mediated activation of type 1 IFN IRF3 mediated activation of type 1 IFN LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production Regulation of innate immune responses to cytosolic DNA IRF3-mediated induction of type I IFN Interferon gamma signaling TICAM1-dependent activation of IRF3/IRF7 Interferon alpha/beta signaling TRAF3-dependent IRF activation pathway TRAF6 mediated IRF7 activation Negative regulators of DDX58/IFIH1 signaling Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon

Search Results for: TBK1